glp 1 rezeptor PDB-101: Molecule of the Month: GLP-1 Receptor Agonists Spatiotemporal GLP-1 and GIP receptor

FDA testing found up to 40% of online peptides contained incorrect dosages or undeclared ingredients

Weight loss with GLP-1 medications is generally steady and sustainable rather than rapid

David Ricks, Chair and Chief Executive Officer of Eli Lilly, noted that fewer than one in ten people who could benefit from a GLP-1 therapy are currently taking one, citing access barriers, stigma, and the complexity of existing treatment options

Its important to understand more is not better and often the dosing as prescribed by the manufacturer is too high/aggressive

Statements Author contributions AT: Writing original draft, Writing review & editing

For each experiment, two to three rats were decapitated